HDAC9 and acute myeloid leukemia: As an aside, it is worth noting that histone deacetylase (HDAC) inhibitors vorinostat and panobinostat are approved for use in cutaneous T-cell lymphoma and multiple myeloma, respectively, and that the oral HDAC inhibitor pracinostat is currently being tested in a phase 3 setting in combination with azacitidine in elderly patients with AML (NCT03151408).